Human Genome Epidemiology Literature Finder
Records 1 - 10 (of 10 Records) |
Query Trace: Colorectal Neoplasms and VEGFA[original query] |
---|
VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2011 Oct 24 (10): 1404-12. Vlajnic Tatjana, Andreozzi Maria Carla, Schneider Sandra, Tornillo Luigi, Karamitopoulou Eva, Lugli Alessandro, Ruiz Christian, Zlobec Inti, Terracciano Lui |
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PloS one 2013 8 (7): e66774. Loupakis Fotios, Cremolini Chiara, Yang Dongyun, Salvatore Lisa, Zhang Wu, Wakatsuki Takeru, Bohanes Pierre, Schirripa Marta, Benhaim Leonor, Lonardi Sara, Antoniotti Carlotta, Aprile Giuseppe, Graziano Francesco, Ruzzo Annamaria, Lucchesi Sara, Ronzoni Monica, De Vita Ferdinando, Tonini Giuseppe, Falcone Alfredo, Lenz Heinz-Jos |
VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival. Molecular carcinogenesis 2014 Feb 53 Suppl 1 E140-50. Slattery Martha L, Lundgreen Abbie, Wolff Roger |
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC research notes 2014 7 (1): 260. Bécouarn Yves, Cany Laurent, Pulido Marina, Beyssac Richard, Texereau Patrick, Le Morvan Valérie, Béchade Dominique, Brunet René, Aitouferoukh Sofiane, Lalet Caroline, Mathoulin-Pélissier Simone, Fonck Marianne, Robert Jacqu |
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics 2015 Nov . Rollin Jérôme, Payancé Audrey, Gouilleux-Gruart Valérie, Boisdron-Celle Michelle, Azzopardi Nicolas, Morel Alain, Gruel Yves, Paintaud Gilles, Gamelin Erick, Watier Hervé, Lecomte Thier |
Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. The pharmacogenomics journal 2016 Nov . Morgen E K, Lenz H-J, Jonker D J, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis C S, Dobrovic A, O'Callaghan C J, Liu |
Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. Cancer research and treatment : official journal of Korean Cancer Association 2016 Jul 48 (3): 990-7. Kim Mi-Jung, Han Sae-Won, Lee Dae-Won, Cha Yongjun, Lee Kyung-Hun, Kim Tae-Yong, Oh Do-Youn, Kim Se Hyung, Im Seock-Ah, Bang Yung-Jue, Kim Tae-Y |
Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab. Oncotarget 2017 Dec 8 (62): 105472-105478. Cui Wei, Li Feng, Yuan Qiang, Chen Gang, Chen Cailing, Yu |
Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2021 Dec . Park Hanla A, Seibold Petra, Edelmann Dominic, Benner Axel, Canzian Federico, Alwers Elizabeth, Jansen Lina, Schneider Martin, Hoffmeister Michael, Brenner Hermann, Chang-Claude Jen |
Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment. CPT: pharmacometrics & systems pharmacology 2022 7 11 (10): 1328-1340. Karatza Eleni, Papachristos Apostolos, Sivolapenko Gregory B, Gonzalez Dani |
- Page last reviewed:Feb 1, 2024
- Content source: